Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis

Advances in Radiation Therapy Treatment Systems

This article ran as an introduction to the Radiation Therapy Systems comparison chart

Accuray Radixact

Accuray Radixact

While radiation therapy as a discipline is well into maturity, new technology advances continue to drive the field forward. The following is a roundup of some of the most significant products to launch or be introduced in the last 12 months.


Image-guided Radiation Therapy Systems

Image-guided radiation therapy (IGRT) offers a more precise and accurate form of treatment than standard photon radiotherapy, incorporating imaging during treatment delivery to more closely assess tumor response. One imaging modality in particular that has shown promise in this application is magnetic resonance imaging (MRI) for its ability to provide real-time anatomical and functional information without giving added radiation dose to the patient.

Viewray was the first to market with a commercial MRI-guided radiotherapy system in the U.S., earning U.S. Food and Drug Administration (FDA) approval for the MRIdian system in 2012. In February of this year, Viewray earned FDA approval for new soft tissue visualization capabilities on MRIdian, including:

  • Expanded high-definition visualization and enhanced contrast between different tissues to assist with tissue visualization
  • and contouring;
  • The potential to aid in the assessment and prediction of tumor response to radiotherapy with “DWI,” a diffusion weighted imaging feature that tracks treatment progress by distinguishing between tumor and normal tissues;
  • Faster, brighter, more detailed anatomical planar imaging to strike tumors with greater precision and accuracy. This is achieved through proprietary technology that allows for a 2X increase in MRI speed (to 8 frames per second), a 2X increase in image resolution and a 2X improvement in MR signal-to-noise ratio (SNR); and
  • Potential reduction in treatment delivery time through enhanced multileaf collimator (MLC) speed.

Elekta became the second entrant to the market in late 2018 following FDA clearance of its Elekta Unity MR-Linac. Created through a partnership with Philips Healthcare, the system employs a 1.5 Tesla (T) magnet for imaging modeled on the Philips Ingenia MRI but has been modified for radiotherapy applications. (Viewray’s MRIdian uses a 0.3T magnet.) With the real-time imaging capabilities of Unity, users can see if the target area moves out of the treatment beam and can pause or adjust therapy accordingly.

Canadian startup MagnetTx Oncology Solutions is looking to become the third vendor in the MR-linac market with its Aurora-RT system that is pending FDA 510(k) clearance. The prototype was developed at the University of Alberta Cross Cancer Institute in 2008, and the first human-size unit was installed in Canada in 2014. Aurora-RT features a 110 cm bore — larger than most MR-linacs in development, according to the company — allowing patient and table to be moved so the tumor remains in isocenter. Other features include a 120-leaf MLC and a 0.5T cryogen-free MR system that requires no helium venting.

Reflexion Medical introduced a different approach to IGRT that it calls biology-guided therapy at the American Society of Radiation Oncology (ASTRO) 2018 annual meeting. The system they displayed combines a linear accelerator and a positron emission tomography/computed tomography (PET/CT) scanner into a single gantry. Instead of tracking tumors with live MRI, the system uses the PET signals of the tumor itself to triangulate its position in the body. The onboard 16-slice fan beam CT creates images in less than 30 seconds with very fast spin. The company says this could eliminate the need for fiducial markers and respiratory gating, which would also reduce the margins necessary to ensure healthy tissue is spared from additional toxicity.   


Patient Positioning

Several vendors have recently introduced new ways to better track and adjust patient positioning to maximize treatment efficiency while minimizing damage to healthy tissue. Accuray’s Radixact platform features CTrue IR technology, an iterative reconstruction algorithm used with onboard imaging. CTrue IR employs the linear accelerator’s therapy beam for imaging, which allows the radiation oncologist to see the exact beam line view of the anatomy rather than the side view typically seen with separate onboard imaging. The software also offers crisper images to better delineate soft tissues.

Accuray also recently launched Synchrony motion tracking and correction technology for the Radixact platform. This new feature adds intrafraction motion synchronization capabilities to the RT system, enabling real-time tracking, visualization and correction for tumor motion during treatment. The company said this can improve dose accuracy and treatment times compared to conventional radiation therapy systems.

Respiratory gating is a common practice in radiation oncology to account for the motion associated with breathing and other bodily processes that might disrupt treatment plans. At the 2018 annual meeting of the American Association of Physicists in Medicine (AAPM), C-Rad showed a new iteration of its motion tracking system designed for respiratory gating. cBreath employs three cameras that work in tandem with a CT scan to help triangulate the patient and show positioning. The system produces a color-coded image to help align the patient with the reference CT — red means that part of the patient is too high, yellow indicates they’re too low, green indicates a reference surface and blue reflects the live surface of the patient on the table. The cBreath technology uses visible light, so there is no additional dose to the patient.

Civco introduced a new patient immobilizer for the head and neck at AAPM 2018. The Solstice device allows the head and neck to be tilted in different positions to better match the treatment plan during stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). The device received FDA clearance in October 2018.


3-D Printing in Radiotherapy

Several companies in the last 12 months have introduced 3-D printing capabilities to enhance the delivery of radiation therapy. Civco and Dot Decimal now offer the ability to 3-D print boluses for radiation therapy systems to modify the dose delivered to the patient. The technologies take a patient’s CT scan and use it to generate the bolus design, which can then be produced in the 3-D printer.



Related content:

Radiation Therapy Systems comparison chart

Related Content

Radiology, radiation therapy, PACS, Enterprise image, X-ray, DR Systems, CT, MRI, contrast, ultrasound, VNA, product comparisons, comparison charts on ITN magazine.
Feature | February 17, 2021
Imaging Technology News (ITN) maintains more than 40
Immunotherapy-based precision medicine clinical trials being developed

Getty Images

News | Prostate Cancer | February 16, 2021
February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits fr
Phase III clinical trial of men with a clinical suspicion of prostate cancer finds MRI with targeted biopsies to be more accurate at diagnosis and less intrusive than current standard
News | Magnetic Resonance Imaging (MRI) | February 08, 2021
February 8, 2021 — The results of a Phase III randomized clinical trial have shown that when it comes to detecting cl

Chart courtesy of the American Cancer Society

News | Breast Imaging | February 08, 2021
February 8, 2021 — Cancer ranks as a leading cause of death in every country in the world, and, for the first time,
Real Time Imaging Technologies LLC iannounced that it has received U.S. Patent No. 10,898,070 IMAGING APPARATUS AND METHODS which covers the company’s methods for incorporating microlens into X-ray imaging detectors that enables significantly lower radiation dose without compromising image resolution.

Getty Images

News | Radiation Dose Management | February 05, 2021
February 5, 2021 — 

Images in 69-year-old man with biopsy-confirmed Gleason score 7 (3+4) prostate cancer. (a) Pretreatment axial T2-weighted fast spin-echo MRI scan (repetition time msec/echo time msec, 3820/97) shows tumor in midline anterior transition zone (arrow). (b) Intraoperative MRI scan shows contoured rectal wall (red line), prostate margin (blue outline), and region of interest (orange outline). Because the urethra was included in planned treatment volume, a suprapubic catheter was placed for continuous bladder drainage during treatment. (c) Intraoperative MRI scan shows focused ultrasound beam path (blue) overlaid on treatment plan. Rectangles illustrate each sonication spot. (d) Thermal map image obtained during treatment with heat deposition color coded in red overlaid on sonication spot. (e) Axial gadopentetate dimeglumine-enhanced MRI scan (230/2.97) obtained immediately after treatment shows devascularized ablated volume (arrows). (f) Corresponding T2-weighted fast spin-echo MRI scan (3820/97) at 5 months after ablation shows complete involution of transition zone. All seven cores from treatment area margins were negative for cancer at biopsy. Image courtesy of the Radiological Society of North America

News | Prostate Cancer | February 05, 2021
February 5, 2021 — A technique that delivers...
Bright spots indicate that cancer cells have responded to a one-day challenge with estrogen in this positron emission tomography (PET) scan of a woman with breast cancer. In a small study, researchers at Washington University School of Medicine in St. Louis found that only women whose tumors responded to estrogen challenge benefited from hormone therapy. The findings could help doctors choose the treatments most likely to help their patients. Image courtesy of Farrokh Dehdashti

Bright spots indicate that cancer cells have responded to a one-day challenge with estrogen in this positron emission tomography (PET) scan of a woman with breast cancer. In a small study, researchers at Washington University School of Medicine in St. Louis found that only women whose tumors responded to estrogen challenge benefited from hormone therapy. The findings could help doctors choose the treatments most likely to help their patients. Image courtesy of Farrokh Dehdashti

News | PET Imaging | February 03, 2021
February 3, 2021 — Hormone therapy commonly is given as a targeted treatment for women whose cancer cells carry recep